MacroGenics said today it has regained full global rights to the Phase I cancer compound enoblituzumab (MGA271), after Servier opted not to exercise its option to develop and commercialize the B7-H3-targeting monoclonal antibody in Europe and other countries under a four-year-old collaboration.
 

MacroGenics said it intended to advance enoblituzumab and two other potential therapies targeting B7-H3—a member of the B7 family of immune regulators—for which it also has global development and commercialization rights.“Servier’s decision enables us to integrate development and commercial strategies across these assets in the future,” MacroGenics president and CEO Scott Koenig, M.D., Ph.D., said in a statement.
 

That collaboration generated a $20 million upfront payment from Servier and could have resulted in up to $450 million for MacroGenics.MacroGenics said a separate collaboration with Servier focused on the development of DART molecules will continue and was not affected by the end of the B7-H3 alliance.